AI in practice: 4 real-world use cases in health and life sciences
March 5, 2026 |
Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it is applied to clearly defined challenges, embedded into existing workflows, and paired with deep domain expertise.
Across health and life sciences, organizations are moving beyond experimentation and focusing on how AI can support better decisions, more efficient operations, and clearer communication. At Inizio, these capabilities are central to how we drive Intelligent Commercialization™ – connecting data, insight, and expertise to help teams act with greater clarity and confidence. The following four use cases from across Inizio illustrate what that looks like in real-world settings – supporting operational performance, insight generation, engagement strategies, and strategic decision-making across the commercialization journey.
How did Inizio Engage scale call monitoring with AI-powered speech analytics?
Traditional call monitoring approaches often limit both scale and consistency, with only a small proportion of interactions reviewed and feedback delivered retrospectively. In this use case, Inizio Engage applied AI-powered speech analytics to analyze calls at scale, enabling patterns, risks, and performance indicators to be identified more efficiently and consistently across large volumes of interactions.
By automating the analysis of call content, our client was able to move beyond manual sampling and focus attention where it mattered most. The approach supported more targeted coaching and quality assurance, helping improve agent performance while maintaining oversight across a significantly broader set of calls.
How did Inizio Evoke turn digital insights into smarter HCP engagement with hematologic oncologists?
Engaging hematologic oncologists effectively requires a clear understanding of how they seek, consume, and respond to information. In this example, Inizio Evoke used Narratev™, a product in their Cognitev™ platform, to uncover real-world engagement behaviors, moving beyond surface-level metrics to identify patterns that could inform more relevant and timely interactions.
By translating these insights into practical recommendations, our client was able to align engagement strategies more closely with oncologists’ information needs and preferences. This helped support more focused decision-making and enabled engagement approaches that were better grounded in observable behavior rather than assumptions.
How did Inizio Ignite accelerate indication strategy in rare endocrine disorders?
Developing an effective indication strategy in rare endocrine disorders requires teams to assess a wide range of potential opportunities while balancing scientific feasibility, commercial considerations, and internal alignment. In this example, Inizio Ignite used AssetNav, part of their Navigator AI™ platform, to evaluate and prioritize potential indications, enabling more informed and objective strategic discussions.
By applying consistent criteria and integrating insights across functions, teams were able to narrow a broad set of possibilities into a focused, prioritized shortlist. This supported clearer decision-making, faster alignment, and a more repeatable approach to indication planning that could be applied beyond a single strategic exercise.
How did Inizio Medical elevate MSL performance with AI-enabled field intelligence?
Medical Science Liaisons (MSLs) generate vast amounts of valuable insight through their interactions with healthcare professionals, yet much of this intelligence can be difficult to capture, structure, and apply consistently. Inizio Medical built iON AI™ HCP Interact to help transform unstructured field insights into actionable intelligence that could be shared across medical and commercial teams.
By using AI to synthesize insights from MSL activity, organizations can surface emerging themes, identify unmet needs, and support more consistent scientific exchange. This enables MSLs to spend less time on manual reporting and more time on high-value engagement, with clearer visibility into field insights to inform strategy and planning.
Taking AI from potential to practice
The impact of AI is not defined by the technology alone, but by how it is applied to real challenges and real decisions. When paired with human expertise and grounded in strong data foundations, AI becomes a powerful enabler of more focused action and measurable progress.
Rather than replacing existing processes, each example shows AI working alongside teams – extending their ability to monitor, understand, and act at scale. This is how Inizio helps organizations drive Intelligent Commercialization™ – using platforms, products, and solutions to turn insight into action and complexity into clarity across the pharma lifecycle.
Discover how Intelligent Commercialization™ is built to deliver real-world results.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership is celebrating 20 years in business
Watch our short video to see how we have grown. Please note the video comes with some fun, themed music. https://www.researchpartnership.com/news/2017/06/research-partnership-is-celebrating-20-years-in-bus...
Therapy Watch expands oncology and IBD portfolios
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...
Research Partnership announces several new appointments
Research Partnership is delighted to welcome Anne Cunningham and Morten Andersen and announce that Sue Rees has joined our specialist Emerging Markets team.
PMRC San Francisco 2017
We are delighted to be presenting a paper and exhibiting at the Pharmaceutical Market Research Conference 13-14 June in Bay Area close to our new office in San Francisco.Representing Research...
EphMRA Annual Conference 2017
Visit us on stand number 14
Richard Head nominated for EphMRA Award
We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been...
Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report
Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...
EULAR Annual European Congress of Rheumatology 2017
Join us at EULAR Congress 2017 in Madrid, 14-17 June
PEGASUS UNVEILS NEW BRAND IDENTITY AS IT CELEBRATES A YEAR AS PART OF ASHFIELD
Pegasus, an Ashfield company, part of UDG Healthcare plc, has unveiled a new brand identity signaling its successful integration with the global business, a year on from acquisition. Conceived by...